Pregnancy Labeling Changes May Spur Research, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Final regulation eliminates use of letter-based categories to designate level of risk during pregnancy and lactation; in a change from the 2008 proposed rule, information relevant to drug effects on reproductive potential will now be housed in dedicated section.
You may also be interested in...
Exit Interview: US FDA’s Sandra Kweder Reflects On A 30-Year Career As She Heads Into Retirement
Having recently returned from six years overseas as the FDA’s liaison to the European Medicines Agency, ‘now was a good time to try something different,’ Kweder says in a Pink Sheet interview. Her tenure at the agency included numerous leadership roles in CDER as well as spearheading the development of the pregnancy labeling rule.
Pregnancy Labeling: US FDA Ponders Whether Changes Needed To Overcome Risk Misperceptions
Risk Communication Advisory Committee will opine on impact that Pregnancy and Lactation Labeling Rule has had in conveying safety evidence useful to making prescribing decisions for pregnant patients and whether current labeling language can be improved upon.
Pregnancy Labeling Gets A New Look
FDA’s final rule includes narrative summaries of risk information about use during pregnancy and lactation, and it creates a new section relevant to drug effects on reproductive potential.